心力衰竭中的呼吸暂停与表型指导治疗:第一部分:阻塞性睡眠呼吸暂停
本文综述了阻塞性睡眠呼吸暂停(OSA)在心力衰竭(HF)患者中的高患病率及其病理生物学后果,指出观察性研究和小型随机对照试验显示治疗可改善心血管结局,但缺乏长期随机对照试验证实生存获益,且唯一纳入HF患者的阳性气道压治疗试验未显示临床结局改善。鉴于阳性气道压作为HF中睡眠呼吸障碍唯一治疗的地位受到质疑,本综述旨在将近期进展整合入基于表型的OSA管理策略。
要点
- OSA在HF患者中高患病率,包括无症状和有症状的HFrEF及HFpEF患者。
- OSA的急性病理生物学后果包括交感神经过度活跃、氧化应激和炎症,可导致左心室功能进行性恶化、反复住院和超额死亡率。
- 缺乏长期随机对照试验证实治疗OSA可改善HF患者生存,且唯一纳入HF患者的阳性气道压治疗试验未显示临床结局改善。
核心结论
- 需要重新审视HF中OSA管理的长期接受概念,并采用基于表型的方法。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- OSA在HF患者中高度流行,包括HFrEF和HFpEF。
- OSA的急性病理生物学后果包括交感神经过度活跃、氧化应激和炎症,可导致左心室功能进行性恶化、反复住院和超额死亡率。
- 大量观察性研究和少数小型随机对照试验显示治疗可改善SDB的各种心血管后果。
- 没有长期随机对照试验显示治疗OSA可改善HF患者生存。
- 一项阳性气道压治疗OSA的试验纳入HF患者,显示临床结局无改善。
临床怎么用
- 临床管理HF中的OSA应考虑基于表型的方法。
局限性
- 缺乏长期随机对照试验证据。
- 唯一纳入HF患者的阳性气道压治疗试验存在多个重要缺陷。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sleep-disordered breathing (SDB), including OSA and central sleep apnea, is highly prevalent in patients with heart failure (HF). Multiple studies have reported this high prevalence in asymptomatic as well as symptomatic patients with reduced left ventricular ejection fraction (HFrEF), as well as in those with HF with preserved ejection fraction. The acute pathobiologic consequences of OSA, including exaggerated sympathetic activity, oxidative stress, and inflammation, eventually could lead to progressive left ventricular dysfunction, repeated hospitalization, and excessive mortality. Large numbers of observational studies and a few small randomized controlled trials have shown improvement in various cardiovascular consequences of SDB with treatment. There are no long-term randomized controlled trials to show improved survival of patients with HF and treatment of OSA. One trial of positive airway pressure treatment of OSA included patients with HF and showed no improvement in clinical outcomes. However, any conclusions derived from this trial must take into account several important pitfalls that have been extensively discussed in the literature. With the role of positive airway pressure as the sole therapy for SDB in HF increasingly questioned, a critical examination of long-accepted concepts in this field is needed. The objective of this review was to incorporate recent advances in the field into a phenotype-based approach to the management of OSA in HF.
引用
- Javaheri S, Brown LK, Abraham WT, et al. Apneas of Heart Failure and Phenotype-Guided Treatments: Part One: OSA. Chest. 2019. PMID: 31047953. doi:10.1016/j.chest.2019.02.407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。